MedTrace Logo

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

NCT01250496 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2023-03-13

Study results available
· View outcomes & findings →

Summary

The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset) and other side effects related to regadenoson.

Conditions

  • Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan

Interventions

DRUG

Aminophylline

75 mg of intravenous aminophylline

DRUG

Placebo

Matching 0.9 Normal Saline (sterile salt water)administered intravenously.

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250496 on ClinicalTrials.gov